Browse by Audience
Skip to content
Papers of the Week
Evaluating Ubrogepant-related adverse events using the FDA adverse event reporting system.
Authors
Cao B, Gu S, Shen Z, Zhang Y, Shen Y, Chen HAbstract
Migraine has a high prevalence in the population and accounts for 12% of primary headaches. Ubrogepant is used for the treatment of acute migraine, and although some clinical trials have demonstrated the safety of Ubrogepant, its long-term safety in a large sample of the population remains to be investigated.